JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(1):34-40 | DOI: 10.5817/CSF2022-1-34

Cerebroprotective properties of recombinant interleukin-1 receptor - an experimental study

Katherine Shchokina*, Vira Ulanova, Svitlana Drogovoz
Department of Pharmacology and Pharmacotherapy of the National University of Pharmacy, Kharkiv, Ukraine

Optimization of therapy of cerebrovascular disorders (CVD) is one of the most critical health problems. The current treatment regimen of CVD turns out to be often insufficient. Search for new drugs with cerebroprotective and antihypoxic properties is an essential task of modern medicine and pharmacy. Attention to cytokine mechanisms of ischemic brain damage in clinics and experimental research has been increased recently. Interleukin-1 (IL-1) receptor blockade is a perspective way of cerebroprotection that requires a more profound study of its mechanisms. The article contains the results of a study of cerebroprotective and antihypoxic properties of the recombinant IL-1 antagonist raleukin on a model of bilateral carotid occlusion in rats. Recombinant receptor antagonist IL-1 raleukin (15 mg/kg) did not affect basal blood flow in the internal carotid artery of intact group animals. Still, it prevented its decrease approximately three times in case of occlusion of both common carotid arteries followed by reperfusion. Indicators of the cerebroprotective effect of studied medication were reducing the acidotic blood shift flowing from the brain of animals with irreversible bilateral carotid occlusion, neuronal degradation, and weakening.

Keywords: Cerebral ischemia; interleukin-1; raleukin; bilateral carotid occlusion; neuron-specific enolase

Received: November 18, 2021; Accepted: February 4, 2021; Published: January 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Shchokina K, Ulanova V, Drogovoz S. Cerebroprotective properties of recombinant interleukin-1 receptor - an experimental study. Čes. slov. farm. 2022;71(1):34-40. doi: 10.5817/CSF2022-1-34.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shchokіna K. G, Simbirtsev A. S., Ishenko A. M. Shtrygol S., Drogovoz S. Cerebroprotective properties of interleukin 1 receptor antagonist in models of brain lesions of different genesis. Cytokines and inflammation 2012; 1, 52-58.
    2. Helmy A., Guilfoyle M. R., Carpenter K. L., Pickard J. D., Menon D. K., Hutchinson P. J. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood. Flow Metab. 2014; 34(5), 845-851. https://doi.org/10.1038/jcbfm.2014.23 Go to original source... Go to PubMed...
    3. Fahey E., Doyle S. L. IL-1 family cytokine regulation of vascular permeability and angiogenesis. Front. Immunol. 2019; 10, 1423. https://doi.org/10.3389/fimmu.2019.01426. Go to original source... Go to PubMed...
    4. Simi A., Tsakiri N., Wang P., Rothwell N. J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 2007; 35 (5), 1122-1126. https://doi.org/10.1042/BST0351122 Go to original source... Go to PubMed...
    5. Patent UA 96037 (51) IPC (2011) А61K 38/20. The use of recombinant antagonist of interleukin-1 receptors (ARIL-1) as an antialcoholic agent / K. G. Shchokіna, S. Y. Shtrigol, O. M. Іschenko, No u 200912496; appl. 03.12.2009; publ. 26.09.2011.
    6. Greenhalgh A. D., Galea J., Dénes A., Tyrrell P. J., Rothwell N. J. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br. J. Pharmacol. 2010; 160, 153-159. https://doi.org/10.1111/j.1476-5381.2010.00684.x Go to original source... Go to PubMed...
    7. Patent UA 31373 on utility model IPC (2006) A61K 35/66 The use of an antagonist of interleukin-1 receptors as a means of cerebroprotective action / Suprun E. V., Shtrigol S. Y., Іschenko O. M., Suprun O. S. - No u200711672; appl. 22.10.2007; publ. 10.04.2008; Bull. No 7.
    8. Patent UA 33402 on utility model IPC (2006) A61K 38/20 The use of an antagonist of interleukin-1 receptors as a means of antihypoxic action / Suprun E. V., Shtrigol S. Y., Іschenko O. M., Suprun O. S. - No u200800473; appl. 14.01.2008; publ. 25.06.2008; Bull. No 12.
    9. Banwell V., Sena E. S., Macleod M. R. Systematic review and stratified meta-analysis of the efficacy of interleukin- 1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 2009; 18(4), 269-276. https://doi.org/10.1016/j.jstrokecerebrovasdis.2008.11.009 Go to original source... Go to PubMed...
    10. Xia Y. Y., Song S. W., Min Y., Zhong Y., Sheng Y. C., Li R. P. The effects of anakinra on focal cerebral ischemic injury in rats. CNS Neurosci. Ther. 2014; 20, 879-881. https://doi.org/10.1111/cns.12310 Go to original source... Go to PubMed...
    11. Pradillo J. M., Denes A., Greenhalgh A. D. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J. Cereb. Blood Flow Metab. 2012; 32(9), 1810-1819. https://doi.org/10.1038/jcbfm.2012.101 Go to original source... Go to PubMed...
    12. Mulcahy N. J., Ross J., Rothwell N. J., Loddick S. A. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br. J. Pharmacol. 2003; 140, 471-476. https://doi.org/10.1038/sj.bjp.0705462 Go to original source... Go to PubMed...
    13. Mironov A. N. Manual on experimental (preclinical) study of new pharmacological substances. Moscow: IIA "Remedium" 2012.
    14. Ghajari M., Hellyer P. J., Sharp D. J. Computational modelling of traumatic brain injury predicts the location of chronic traumatic encephalopathy pathology. Brain 2017; 140 (2), 333-343. https://doi.org/10.1093/brain/aww317 Go to original source... Go to PubMed...
    15. Garcia J. H., Liu K. F., Relton J. K. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am. J. Pathol. 1995; 147, 1477-1486.
    16. Haupt W. F., Chopan G., Sobesky J., Liu W.C., Dohmen C. Prognostic value of somatosensory evoked potentials, neuron-specific enolase, and S100 for short-term outcome in ischemic stroke. J. Neurophysiol. 2016; 115, 1273-1278. https://doi.org/10.1152/jn.01012.2015 Go to original source... Go to PubMed...
    17. Anand N., Stead L. G. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc. Dis. 2005; 20(4), 213-219. https://doi.org/10.1159/000087701 Go to original source... Go to PubMed...
    18. Basu A., Krady J. K., O'Malley M. The type 1 interleukin- 1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J. Neurosci. 2002; 22(14), 6071-6082. https://doi.org/10.1523/JNEUROSCI.22-14-06071.2002 Go to original source... Go to PubMed...
    19. Thom J. G., Reeder E. L., Collins S. M., Gopalan P., Robson M. J. Contributions of interleukin-1 receptor signaling in traumatic brain injury. Front. Behav. Neurosci. 2020; 13, 287. https://doi.org/10.3389/fnbeh.2019.00287 Go to original source... Go to PubMed...
    20. Loddick S. A., Rothwell N. J. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab. 1996; 16, 932-940. https://doi.org/10.1097/00004647-199609000-00017 Go to original source... Go to PubMed...
    21. Belayev L., Alonso O. F., Busto R., Zhao W., Ginsberg, M. D. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996; 27, 1616-1622. https://doi.org/10.1161/01.str.27.9.1616 Go to original source... Go to PubMed...
    22. Lee J. H., Kam E. H., Kim J. M., Kim S. Y., Kim E. J., Cheon S. Y., Koo B. N. Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat. Model. Biomol. Ther. (Seoul) 2017; 25(2), 149-157. https://doi.org/10.4062/biomolther.2016.050 Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.